Is Table S1 presenting a description of study populations, Table S2 presenting KI67 immunohistochemistry reagents and antigen retrieval protocols according to study groups, Table S3 presenting the association of clinical and pathological characteristics with high (>12 %) and low (≤12 %) KI67 categories among 5520 ER-positive breast cancer cases, Table S4 presenting the association of clinical and pathological characteristics with high (>12 %) and low (≤12 %) KI67 categories among 2049 ER-negative breast cancer cases, Table S5 presenting cross-classification of visual and automated KI67 score categories, Table S6 presenting a multivariate model for the association of KI67 with 10-year BCSS among 5520 ER-positive patients, and Table S7 presen...
Patient characteristics of the 6,248 patients shown by trial. Table S2. National Cancer Institute Co...
Prognostic factors for overall survival (Univariate) (N = 104). Table S2. Prognostic factors for ove...
Patient characteristics. Table S2. Antibodies and immunostaining protocols. Table S3. Associations b...
Is Figure S3 showing KaplanâMeier survival curves for the 10-year BCSS according to strata (high a...
Is Figure S2 showing ROC curve for the discriminatory accuracy of continuous automated KI67 scores a...
Results of disease-free survival analysis by Cox proportional hazards model for the the Ki67Low grou...
Supplementary Figures and Tables. This file contains the following figures and tables: Validation of...
Multivariate analysis including Estrogen and Her2 receptor status. This additional file comprises 3 ...
Results of a multivariate survival analysis on the influence of clinicopathological variables includ...
Disease-Free Survival (DFS) [Panel A and C] and Overall Survival (OS) [Panel B and D], according to ...
Figure S1. Survival analysis (Kaplan–Meier estimates) with breast cancer-specific survival (BCSS) as...
Table S1. Minimum criteria required for the diagnosis of IBC. Table S2. Correlation between PD-L1 an...
Figure S1. KaplanâMeier survival analysis of baseline hematologic parameters (NLR, PLR), TILs CD8+...
Table S1. Patients’ clinical and biological characteristics. Table S2. Characteristics of brain meta...
Table S1: Distribution of clinico-pathological variables between patients with sufficient tumor mate...
Patient characteristics of the 6,248 patients shown by trial. Table S2. National Cancer Institute Co...
Prognostic factors for overall survival (Univariate) (N = 104). Table S2. Prognostic factors for ove...
Patient characteristics. Table S2. Antibodies and immunostaining protocols. Table S3. Associations b...
Is Figure S3 showing KaplanâMeier survival curves for the 10-year BCSS according to strata (high a...
Is Figure S2 showing ROC curve for the discriminatory accuracy of continuous automated KI67 scores a...
Results of disease-free survival analysis by Cox proportional hazards model for the the Ki67Low grou...
Supplementary Figures and Tables. This file contains the following figures and tables: Validation of...
Multivariate analysis including Estrogen and Her2 receptor status. This additional file comprises 3 ...
Results of a multivariate survival analysis on the influence of clinicopathological variables includ...
Disease-Free Survival (DFS) [Panel A and C] and Overall Survival (OS) [Panel B and D], according to ...
Figure S1. Survival analysis (Kaplan–Meier estimates) with breast cancer-specific survival (BCSS) as...
Table S1. Minimum criteria required for the diagnosis of IBC. Table S2. Correlation between PD-L1 an...
Figure S1. KaplanâMeier survival analysis of baseline hematologic parameters (NLR, PLR), TILs CD8+...
Table S1. Patients’ clinical and biological characteristics. Table S2. Characteristics of brain meta...
Table S1: Distribution of clinico-pathological variables between patients with sufficient tumor mate...
Patient characteristics of the 6,248 patients shown by trial. Table S2. National Cancer Institute Co...
Prognostic factors for overall survival (Univariate) (N = 104). Table S2. Prognostic factors for ove...
Patient characteristics. Table S2. Antibodies and immunostaining protocols. Table S3. Associations b...